AbbVie, Roche combo treatment meets main goal of leukemia trial

AbbVie Inc and Roche Holding AG said on Wednesday their immunotherapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker's cancer drug in a late-stage trial.